IFNG
EmergingIFN-gamma release underlies IGRA testing, now preferred over the tuberculin skin test for diagnosing latent TB.
Interferon gamma is released by immune cells fighting TB infection, and measuring this response (rather than a traditional skin test) is now a preferred way to diagnose latent TB, especially in people who received the BCG vaccine as children.
Interferon gamma (IFN-γ) is a cytokine central to cell-mediated immune responses against intracellular pathogens, most notably Mycobacterium tuberculosis.
IFN-γ release in response to TB-specific antigens is the basis for interferon-gamma release assays (IGRAs), used to diagnose latent tuberculosis infection.
IGRAs (e.g., QuantiFERON-TB) have become a preferred alternative to the traditional tuberculin skin test, since they aren't affected by prior BCG vaccination — a real practical advantage in vaccinated populations where skin tests can be falsely positive.
A positive IGRA in a patient without active TB symptoms supports latent TB treatment consideration (isoniazid or rifampin-based regimens) per current public health guidelines, without the false-positive risk that BCG vaccination creates for skin testing.
Not affected by prior BCG vaccination, a key practical advantage over the traditional skin test.
- General infectious disease reference literature on interferon-gamma release assays (IGRAs) for latent tuberculosis diagnosis.